ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.9492
0.03%
Brent Oil
84.115
0.69%
Bitcoin
57,793.47
-0.76%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. AcelRX Pharmaceuticals Inc (ACRX)

  7. AcelRX Pharmaceuticals Inc (ACRX) Noticias

ACRX AcelRX Pharmaceuticals Inc

0.86
0.00 (0.00%)
Pre Mercado
Última actualización: 19:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
AcelRX Pharmaceuticals Inc ACRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 0.86 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.86
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202415:25EDGAR2Form ARS - Annual Report to Security Holders
29/4/202415:24EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/4/202415:23EDGAR2Form DEF 14A - Other definitive proxy statements
19/4/202415:37EDGAR2Form 8-K - Current report
21/3/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/3/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/3/202417:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202408:17EDGAR2Form 8-K - Current report
09/1/202408:05PRNUSAcelRx Announces Rebranding With Name Change to Talphera,..
14/12/202307:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202315:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202315:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202307:30PRNUSAcelRx Pharmaceuticals Announces Publication of Study..
22/11/202315:38EDGAR2Form S-3 - Registration statement under Securities Act of..
22/11/202315:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/11/202305:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:14EDGAR2Form 8-K - Current report
08/11/202315:05PRNUSAcelRx Reports Third Quarter 2023 Financial Results and..
07/11/202315:05PRNUSAcelRx to Host KOL Panel Discussion on Current Anticoagulant..
26/10/202315:30PRNUSAcelRx to Host Third Quarter 2023 Financial Results Call and..
20/10/202315:30EDGAR2Form 8-K - Current report
10/10/202315:17EDGAR2Form 8-K - Current report
05/10/202315:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/10/202315:30EDGAR2Form 8-K - Current report
03/10/202307:30PRNUSAcelRx Receives IDE Approval for Niyad and Advances to a..
22/9/202316:18EDGAR2Form 8-K - Current report
11/9/202318:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202307:30PRNUSAcelRx Pharmaceuticals to Participate in the H.C. Wainwright..
28/8/202305:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/8/202305:34EDGAR2Form DEF 14A - Other definitive proxy statements
25/8/202315:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202311:45EDGAR2Form 144 - Report of proposed sale of securities
24/8/202315:23EDGAR2Form 144 - Report of proposed sale of securities
10/8/202316:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:10EDGAR2Form 8-K - Current report
10/8/202315:05PRNUSAcelRx Reports Second Quarter 2023 Financial Results and..
09/8/202316:29EDGAR2Form 424B7 - Prospectus [Rule 424(b)(7)]
02/8/202305:06EDGAR2Form S-3 - Registration statement under Securities Act of..
27/7/202315:05PRNUSAcelRx to Host Second Quarter 2023 Financial Results Call..
21/7/202307:15EDGAR2Form 8-K - Current report
21/7/202307:00PRNUSAcelRx Pharmaceuticals Announces Closing of Previously..
18/7/202307:00PRNUSAcelRx Pharmaceuticals Announces $10 Million Private..
10/5/202315:05PRNUSAcelRx Pharmaceuticals Reports First Quarter 2023 Financial..

Su Consulta Reciente

NASDAQ
ACRX
AcelRX Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados